By: Nana Karikari, Senior Global Affairs Correspondent
The United States Food and Drug Administration has granted authorization for a generic variant of the world’s sole bi-annual HIV prevention injection. This regulatory action represents a major breakthrough toward delivering the drug rapidly and affordably to 120 low- and middle-income nations.
The announcement was delivered on Monday by the generic pharmaceutical company alongside collaborative organizations that helped fast-track the medication, known as lenacapavir.
In target recipient countries, the medicine is projected to cost $40 per year for each patient (approximately GH₵466). This price point matches the current annual expense of daily preventive pills. However, the injectable regimen provides far greater convenience than oral tablets due to its infrequent dosing schedule, and two landmark clinical trials showed that the shots nearly eliminated new infections among high-risk individuals.
Global Health Leaders Emphasize Impact on Transmission
Patients frequently struggle to maintain daily oral medication schedules.
“And if you do not take it, you cannot get protected against HIV,” said Carmen Pérez Casas, HIV lead for Unitaid, a global health grant-making agency. “With lenacapavir, we are much more hopeful.”
Health advocates anticipate that the drug will substantially lower overall HIV transmission rates, AIDS diagnoses, and mortality. Figures from the World Health Organization show that 41 million people globally were living with HIV last year, while 570,000 individuals succumbed to HIV-related illnesses.
Deploying an affordable, high-quality generic alternative opens vital new avenues for international health initiatives.
“We could help to scale this to the 20 million people around the world who need PrEP,” said Carolyn Amole, who leads the HIV program at the Clinton Health Access Initiative, referring to pre-exposure prophylaxis taken prior to viral exposure. “And if we scale to those levels, we can actually begin to bring an end to the HIV epidemic.”
Patent Protections and American Price Differences
Distribution of the new generic version is strictly prohibited within the United States. A brand-name formulation called Yeztugo, created by Gilead Sciences and cleared by regulators last year, retains full domestic patent protection.
In the U.S., Yeztugo carries an annual wholesale list price of $28,218 (approximately GH₵328,740) before insurance adjustments. Gilead representatives state that this pricing remains competitive with other forms of PrEP on the market.
The FDA processed the generic drug under a long-standing regulatory program intended to guarantee the efficacy of HIV treatments procured by the U.S. government for international aid programs. Authorization by American regulators regularly helps expedite secondary approvals from domestic health boards in developing countries. The designation is formally classified as “tentative,” which serves as the standard FDA status for generic formulations while originators maintain active U.S. patents.
Corporate Licensing Deals and Supply Chain Expansion
Gilead previously served as the exclusive producer of lenacapavir, resulting in global supply shortfalls across developing markets. To remedy these shortages, Gilead negotiated royalty-free voluntary licensing agreements with six generic manufacturers. These licenses permit generic production and distribution across designated territories in sub-Saharan Africa, Asia, and Latin America.
“We share the sense of urgency around expanding access to lenacapavir for HIV prevention,” a Gilead spokesperson said in an official statement. “We believe we have enabled the fastest and most sustainable path to expanding access for communities most affected by HIV.”
The initial generic product was engineered in India by Dr. Reddy’s Laboratories under a joint framework facilitated by Unitaid, the Clinton Health Access Initiative, and Wits RHI, an African health research organization. The partners aimed to accelerate production while guaranteeing an accessible price point. Generic formulations from the remaining five licensed producers are still awaiting FDA review.
Clinical Protocol, Risks, and Global Distribution Roadmap
Despite its high effectiveness, lenacapavir requires specific clinical management prior to administration. Common side effects reported by patients include injection site reactions, headaches, and nausea.
Healthcare workers must verify that patients are HIV-negative before administering the first dose and prior to every subsequent semi-annual injection. Clinical data indicates that administering lenacapavir to patients with undetected HIV can provoke drug-resistant viral strains.
“For any kind of PrEP … you need to have HIV testing in advance,” said Saiqa Mullick, director of implementation science at Wits RHI. “For many of the low- and middle-income countries, that is a rapid test.”
Initial deliveries of generic lenacapavir are slated to begin in select regions within weeks. However, distribution may move more slowly in nations that mandate independent domestic regulatory evaluations prior to local rollout.
Global health leaders stress that regulatory approval represents only the beginning of a larger operational effort.
“The work is not done. Now, we need the funding to actually buy it for everyone who needs it and then we need to do the hard work of getting it to the millions of people who need it and want it,” Amole said. “But this is a great milestone.”
Despite lingering implementation challenges, public health experts remain optimistic about the future of viral prevention.
“Now,” Casas said, “we have the tools.”
Bridging Science and Delivery in Global Health
The approval of generic lenacapavir demonstrates how public-private partnerships and regulatory flexibility can bring advanced biomedical innovations to low-income populations.
While generic licensing and price reductions clear major hurdles, the final outcome depends on securing procurement funding, maintaining reliable supply chains, and strengthening local clinical testing infrastructure.
As health authorities prepare for implementation across sub-Saharan Africa and beyond, global health programs face a crucial test in turning scientific breakthroughs into a lasting end to the HIV pandemic.












































